SERCA2氧化还原C674的取代通过激活IRE1α/XBP1s通路促进肺血管重塑

2022-06-28 网络 网络

肺动脉高压(PH)是一种以肺血管重构为特征的危及生命的疾病,其中肺动脉平滑肌细胞(PASMCs)的过度增殖起着重要作用。研究阐明了 C674 氧化失活对肺血管重塑和 PH 发展的因果影响。

肺动脉高压(PH) 是一种危及生命的疾病,静息时平均肺动脉压 (PAP) ≥ 25 mmHg。PH临床上分为五组。第 1 组是肺动脉高压 (PAH),其他都与各种疾病有关。PAH 是一种特别严重和渐进的形式,临床起病缓慢,渐进恶化,其特征是丛状病变。肺血管重构是PH的主要原因。由于 PH 患者的肺样本有限且缺乏合适的动物模型来模拟人类 PH,因此 PH 的发病机制仍存在争议。

肌质/内质网 Ca 2+ ATP 酶 (SERCA)通过将 Ca2+从细胞质转运到肌质网 (SR) 和内质网 (ER)来维持 Ca2+稳态,以维持细胞质中的低 Ca2+ 浓度和SR/ER 中的高 Ca2+浓度。SERCA2(小鼠基因Atp2a2 ,人基因ATP2A2)是血管SERCA的主要亚型,主要包括Atp2a2a和Atp2a2b基因型,其中Atp2a2b是管家基因。半胱氨酸674(C674)的S-谷胱甘肽化在生理条件下调节SERCA2的活性,但在活性氧(ROS)增加的病理情况下,这种修改被其不可逆的氧化所阻止。细胞内 Ca2+水平升高是众所周知的平滑肌细胞 (SMC) 增殖的原因。SERCA2活性的抑制诱导缺氧肺静脉重塑。SERCA2a 的减少与野百合碱诱导的大鼠肺动脉 (PA) 重塑有关。C674 其氧化失活和 SERCA2b 在肺血管重塑中的作用仍不清楚。在这里,我们使用杂合SERCA2C674S 敲入小鼠 (SKI),其中 C674 被丝氨酸(S674) 取代,表明部分 C674 氧化失活。结果表明,SKI 发生了类似于人类 PH 的显著肺血管重塑,并且其右心室收缩压 (RVSP) 随着年龄的增长而适度增加。在肺动脉平滑肌细胞 (PASMCs) 中,S674 取代 C674 通过激活需要酶 1 α (IRE1α )和剪接 X-box 结合蛋白 1 (XBP1s) 途径的肌醇来加速细胞周期并促进细胞增殖。类似于 SERCA2a 9, SERCA2b 对于抑制 PASMCs 的增殖也很重要。本研究提供了一种 SERCA2 功能障碍促进 PASMC 增殖的新机制,即通过激活 IRE1α / XBP1s 通路,并首次证实抑制 IRE1α / XBP1s 通路可防止肺血管重塑。

图文说明:

半胱氨酸674(C674)是维持内质网(ER)Ca2+平衡的关键。它的不可逆氧化通过激活肌醇需求酶1α(IRE1α)/拼接的X-box结合蛋白1(XBP1s)通路而引起肺血管重塑。抑制IRE1α/XBP1s通路可抑制C674失活引起的肺血管重塑。

研究结果:

1.缺氧会增加SERCA2 C674的不可逆氧化,并减少肺和PASMCs中SERCA2的含量;

2.用S674取代C674会增加右心室压力并诱发肺血管重塑;

3.用S674取代C674,通过加速细胞周期促进PASMC增殖;

4.用S674取代C674诱导ER压力以促进PASMC增殖;

5.XBP1s的上调促进SKI PASMC的增殖;

6.抑制IRE1α/XBP1s途径可抑制SKI PASMC增殖;

7.抑制IRE1α/XBP1s途径可防止SKI肺血管重塑;

8.SERCA2b抑制IRE1α/XBP1s通路和SKI PASMCs的增殖;

研究结论:

SERCA2中的C674,特别是SERCA2b,通过抑制IRE1α/XBP1s途径的激活来限制PASMC的增殖,从而维持肺血管的稳态。SKI发生的肺血管重塑在组织学上与PH患者相似,可能成为肺血管重塑和PH的病因研究和药物筛选的重要工具。SERCA2 C674的氧化失活及其下游的IRE1α/XBP1s途径的激活可能是各种PH的共同机制之一。IRE1α/XBP1s途径和SERCA2可能是PH治疗的潜在目标。

 

参考文献:

Yu W, Xu G, Chen H, Xiao L, Liu G, Hu P, Li S, Kasim V, Zeng C, Tong X. The substitution of SERCA2 redox cysteine 674 promotes pulmonary vascular remodeling by activating IRE1α/XBP1s pathway. Acta Pharm Sin B. 2022 May;12(5):2315-2329. doi: 10.1016/j.apsb.2021.12.025. Epub 2022 Jan 5. PMID: 35646520; PMCID: PMC9136575.

 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1632996, encodeId=32ff16329969c, content=<a href='/topic/show?id=785389e9570' target=_blank style='color:#2F92EE;'>#血管重塑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89795, encryptionId=785389e9570, topicName=血管重塑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=925121977560, createdName=xre2015, createdTime=Fri Jul 15 07:02:07 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007700, encodeId=bd61200e700e9, content=<a href='/topic/show?id=f5cd188033b' target=_blank style='color:#2F92EE;'>#XBP1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18803, encryptionId=f5cd188033b, topicName=XBP1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Tue Aug 16 22:02:07 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709523, encodeId=a12a1e0952318, content=<a href='/topic/show?id=6b416398956' target=_blank style='color:#2F92EE;'>#氧化还原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63989, encryptionId=6b416398956, topicName=氧化还原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d10331728781, createdName=ms3415360956839622, createdTime=Wed Jul 13 17:02:07 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049779, encodeId=1fdb2049e79a2, content=<a href='/topic/show?id=a1aa1880497' target=_blank style='color:#2F92EE;'>#XBP1s#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18804, encryptionId=a1aa1880497, topicName=XBP1s)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Jan 19 18:02:07 CST 2023, time=2023-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224876, encodeId=452e12248e686, content=欢迎关注肺动脉高压研究进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/20220607/95de8f6414f948c0b28f31a22b424c45.jpg, type=image, width=258, height=258)], authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210922/abdffc3f4cb6439aa9fa85372323b9ec/5f4b4012b21a4508af5a117375a9f3e2.jpg, createdBy=1bd41976717, createdName=SophylioJerry, createdTime=Tue Jun 07 01:53:48 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602863, encodeId=a6b816028639c, content=<a href='/topic/show?id=e0b5393680' target=_blank style='color:#2F92EE;'>#CA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3936, encryptionId=e0b5393680, topicName=CA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03ab18968787, createdName=TZF0810, createdTime=Sat Jun 04 08:02:07 CST 2022, time=2022-06-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1632996, encodeId=32ff16329969c, content=<a href='/topic/show?id=785389e9570' target=_blank style='color:#2F92EE;'>#血管重塑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89795, encryptionId=785389e9570, topicName=血管重塑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=925121977560, createdName=xre2015, createdTime=Fri Jul 15 07:02:07 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007700, encodeId=bd61200e700e9, content=<a href='/topic/show?id=f5cd188033b' target=_blank style='color:#2F92EE;'>#XBP1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18803, encryptionId=f5cd188033b, topicName=XBP1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Tue Aug 16 22:02:07 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709523, encodeId=a12a1e0952318, content=<a href='/topic/show?id=6b416398956' target=_blank style='color:#2F92EE;'>#氧化还原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63989, encryptionId=6b416398956, topicName=氧化还原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d10331728781, createdName=ms3415360956839622, createdTime=Wed Jul 13 17:02:07 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049779, encodeId=1fdb2049e79a2, content=<a href='/topic/show?id=a1aa1880497' target=_blank style='color:#2F92EE;'>#XBP1s#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18804, encryptionId=a1aa1880497, topicName=XBP1s)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Jan 19 18:02:07 CST 2023, time=2023-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224876, encodeId=452e12248e686, content=欢迎关注肺动脉高压研究进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/20220607/95de8f6414f948c0b28f31a22b424c45.jpg, type=image, width=258, height=258)], authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210922/abdffc3f4cb6439aa9fa85372323b9ec/5f4b4012b21a4508af5a117375a9f3e2.jpg, createdBy=1bd41976717, createdName=SophylioJerry, createdTime=Tue Jun 07 01:53:48 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602863, encodeId=a6b816028639c, content=<a href='/topic/show?id=e0b5393680' target=_blank style='color:#2F92EE;'>#CA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3936, encryptionId=e0b5393680, topicName=CA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03ab18968787, createdName=TZF0810, createdTime=Sat Jun 04 08:02:07 CST 2022, time=2022-06-04, status=1, ipAttribution=)]
    2022-08-16 yeye5224612
  3. [GetPortalCommentsPageByObjectIdResponse(id=1632996, encodeId=32ff16329969c, content=<a href='/topic/show?id=785389e9570' target=_blank style='color:#2F92EE;'>#血管重塑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89795, encryptionId=785389e9570, topicName=血管重塑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=925121977560, createdName=xre2015, createdTime=Fri Jul 15 07:02:07 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007700, encodeId=bd61200e700e9, content=<a href='/topic/show?id=f5cd188033b' target=_blank style='color:#2F92EE;'>#XBP1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18803, encryptionId=f5cd188033b, topicName=XBP1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Tue Aug 16 22:02:07 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709523, encodeId=a12a1e0952318, content=<a href='/topic/show?id=6b416398956' target=_blank style='color:#2F92EE;'>#氧化还原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63989, encryptionId=6b416398956, topicName=氧化还原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d10331728781, createdName=ms3415360956839622, createdTime=Wed Jul 13 17:02:07 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049779, encodeId=1fdb2049e79a2, content=<a href='/topic/show?id=a1aa1880497' target=_blank style='color:#2F92EE;'>#XBP1s#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18804, encryptionId=a1aa1880497, topicName=XBP1s)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Jan 19 18:02:07 CST 2023, time=2023-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224876, encodeId=452e12248e686, content=欢迎关注肺动脉高压研究进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/20220607/95de8f6414f948c0b28f31a22b424c45.jpg, type=image, width=258, height=258)], authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210922/abdffc3f4cb6439aa9fa85372323b9ec/5f4b4012b21a4508af5a117375a9f3e2.jpg, createdBy=1bd41976717, createdName=SophylioJerry, createdTime=Tue Jun 07 01:53:48 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602863, encodeId=a6b816028639c, content=<a href='/topic/show?id=e0b5393680' target=_blank style='color:#2F92EE;'>#CA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3936, encryptionId=e0b5393680, topicName=CA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03ab18968787, createdName=TZF0810, createdTime=Sat Jun 04 08:02:07 CST 2022, time=2022-06-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1632996, encodeId=32ff16329969c, content=<a href='/topic/show?id=785389e9570' target=_blank style='color:#2F92EE;'>#血管重塑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89795, encryptionId=785389e9570, topicName=血管重塑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=925121977560, createdName=xre2015, createdTime=Fri Jul 15 07:02:07 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007700, encodeId=bd61200e700e9, content=<a href='/topic/show?id=f5cd188033b' target=_blank style='color:#2F92EE;'>#XBP1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18803, encryptionId=f5cd188033b, topicName=XBP1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Tue Aug 16 22:02:07 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709523, encodeId=a12a1e0952318, content=<a href='/topic/show?id=6b416398956' target=_blank style='color:#2F92EE;'>#氧化还原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63989, encryptionId=6b416398956, topicName=氧化还原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d10331728781, createdName=ms3415360956839622, createdTime=Wed Jul 13 17:02:07 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049779, encodeId=1fdb2049e79a2, content=<a href='/topic/show?id=a1aa1880497' target=_blank style='color:#2F92EE;'>#XBP1s#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18804, encryptionId=a1aa1880497, topicName=XBP1s)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Jan 19 18:02:07 CST 2023, time=2023-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224876, encodeId=452e12248e686, content=欢迎关注肺动脉高压研究进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/20220607/95de8f6414f948c0b28f31a22b424c45.jpg, type=image, width=258, height=258)], authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210922/abdffc3f4cb6439aa9fa85372323b9ec/5f4b4012b21a4508af5a117375a9f3e2.jpg, createdBy=1bd41976717, createdName=SophylioJerry, createdTime=Tue Jun 07 01:53:48 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602863, encodeId=a6b816028639c, content=<a href='/topic/show?id=e0b5393680' target=_blank style='color:#2F92EE;'>#CA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3936, encryptionId=e0b5393680, topicName=CA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03ab18968787, createdName=TZF0810, createdTime=Sat Jun 04 08:02:07 CST 2022, time=2022-06-04, status=1, ipAttribution=)]
    2023-01-19 119337457
  5. [GetPortalCommentsPageByObjectIdResponse(id=1632996, encodeId=32ff16329969c, content=<a href='/topic/show?id=785389e9570' target=_blank style='color:#2F92EE;'>#血管重塑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89795, encryptionId=785389e9570, topicName=血管重塑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=925121977560, createdName=xre2015, createdTime=Fri Jul 15 07:02:07 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007700, encodeId=bd61200e700e9, content=<a href='/topic/show?id=f5cd188033b' target=_blank style='color:#2F92EE;'>#XBP1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18803, encryptionId=f5cd188033b, topicName=XBP1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Tue Aug 16 22:02:07 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709523, encodeId=a12a1e0952318, content=<a href='/topic/show?id=6b416398956' target=_blank style='color:#2F92EE;'>#氧化还原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63989, encryptionId=6b416398956, topicName=氧化还原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d10331728781, createdName=ms3415360956839622, createdTime=Wed Jul 13 17:02:07 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049779, encodeId=1fdb2049e79a2, content=<a href='/topic/show?id=a1aa1880497' target=_blank style='color:#2F92EE;'>#XBP1s#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18804, encryptionId=a1aa1880497, topicName=XBP1s)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Jan 19 18:02:07 CST 2023, time=2023-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224876, encodeId=452e12248e686, content=欢迎关注肺动脉高压研究进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/20220607/95de8f6414f948c0b28f31a22b424c45.jpg, type=image, width=258, height=258)], authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210922/abdffc3f4cb6439aa9fa85372323b9ec/5f4b4012b21a4508af5a117375a9f3e2.jpg, createdBy=1bd41976717, createdName=SophylioJerry, createdTime=Tue Jun 07 01:53:48 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602863, encodeId=a6b816028639c, content=<a href='/topic/show?id=e0b5393680' target=_blank style='color:#2F92EE;'>#CA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3936, encryptionId=e0b5393680, topicName=CA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03ab18968787, createdName=TZF0810, createdTime=Sat Jun 04 08:02:07 CST 2022, time=2022-06-04, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1632996, encodeId=32ff16329969c, content=<a href='/topic/show?id=785389e9570' target=_blank style='color:#2F92EE;'>#血管重塑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89795, encryptionId=785389e9570, topicName=血管重塑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=925121977560, createdName=xre2015, createdTime=Fri Jul 15 07:02:07 CST 2022, time=2022-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007700, encodeId=bd61200e700e9, content=<a href='/topic/show?id=f5cd188033b' target=_blank style='color:#2F92EE;'>#XBP1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18803, encryptionId=f5cd188033b, topicName=XBP1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Tue Aug 16 22:02:07 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709523, encodeId=a12a1e0952318, content=<a href='/topic/show?id=6b416398956' target=_blank style='color:#2F92EE;'>#氧化还原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63989, encryptionId=6b416398956, topicName=氧化还原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d10331728781, createdName=ms3415360956839622, createdTime=Wed Jul 13 17:02:07 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049779, encodeId=1fdb2049e79a2, content=<a href='/topic/show?id=a1aa1880497' target=_blank style='color:#2F92EE;'>#XBP1s#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18804, encryptionId=a1aa1880497, topicName=XBP1s)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Jan 19 18:02:07 CST 2023, time=2023-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224876, encodeId=452e12248e686, content=欢迎关注肺动脉高压研究进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/20220607/95de8f6414f948c0b28f31a22b424c45.jpg, type=image, width=258, height=258)], authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210922/abdffc3f4cb6439aa9fa85372323b9ec/5f4b4012b21a4508af5a117375a9f3e2.jpg, createdBy=1bd41976717, createdName=SophylioJerry, createdTime=Tue Jun 07 01:53:48 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602863, encodeId=a6b816028639c, content=<a href='/topic/show?id=e0b5393680' target=_blank style='color:#2F92EE;'>#CA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3936, encryptionId=e0b5393680, topicName=CA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03ab18968787, createdName=TZF0810, createdTime=Sat Jun 04 08:02:07 CST 2022, time=2022-06-04, status=1, ipAttribution=)]
    2022-06-04 TZF0810

相关资讯

JAMA:肺动脉高压(PAH)最新定义、病理生理学和患病率

PAH是肺动脉高压(PH)的一种亚型,以肺动脉重构为特征。在美国,PAH 的患病率约为每 100 万成年人 10.6 例。未经治疗,PAH 会发展为右心衰竭和死亡。

Heart:右心室重构在肺动脉高压中的重要性

最近的研究表明 PAH 进展的特征是 RV 尺寸和功能的变化(体积增加和射血分数降低),即使在明显稳定的患者中也是如此,这突出了RV在确定预后中的重要性。

肺动脉高压患者的远程6分钟步行试验:是否需要进一步验证?

肺动脉高压(PAH)是一种相对罕见的心肺血管疾病,六分钟步行测试(6MWT)可以了解慢性肺部疾病患者的功能状况、疾病严重程度和治疗效果。PAH患者的远程6分钟步行试验:是否需要进一步验证?

肺动脉高压患者外周血中BMPR2基因表达降低:病情严重程度的标志?

肺动脉高压(PAH)可由BMPR2基因的致病变体引起。虽然已知BMPR2蛋白表达水平在遗传性PAH(HPAH)患者的肺部组织中降低,但还缺乏评估更容易获得的血液样本中的表达及其临床相关性系统研究。

肺动脉高压(PAH)的亚组都有哪些?

肺动脉高压 (PH) 的临床分类,其中 PAH 是一种亚型,对于了解 PAH 的诊断和治疗方法很重要。根据病理生理学、病因学和对治疗的反应,肺动脉高压进一步分为亚组。

JAMA:肺动脉高压(PAH)的常见临床表现

肺动脉高压(PAH)是肺动脉高压(PH)的一种亚型,以肺动脉重构为特征。在美国,PAH 的患病率约为每 100 万成年人中有 10.6 例。未经治疗,PAH 会发展为右心衰竭和死亡。